Omid Hamid

Omid Hamid

UNVERIFIED PROFILE

Are you Omid Hamid?   Register this Author

Register author
Omid Hamid

Omid Hamid

Publications by authors named "Omid Hamid"

Are you Omid Hamid?   Register this Author

100Publications

101590Reads

21Profile Views

Treatment patterns of malignant melanoma in the United States from 2011 to 2016: a retrospective cohort study.

Curr Med Res Opin 2020 Jan 16;36(1):63-72. Epub 2019 Sep 16.

The Angeles Clinic and Research Institute, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/03007995.2019.1
Publisher Site
http://dx.doi.org/10.1080/03007995.2019.1662688DOI Listing
January 2020

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in -Mutant Melanoma.

Clin Cancer Res 2020 Jan 15;26(1):46-53. Epub 2019 Nov 15.

Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia, and University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-4180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942621PMC
January 2020

Quantitative Metastatic Lymph Node Burden and Survival in Merkel Cell Carcinoma.

J Am Acad Dermatol 2020 Jan 16. Epub 2020 Jan 16.

Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.12.072DOI Listing
January 2020

Intratumoral Immunotherapy-Update 2019.

Oncologist 2019 Nov 29. Epub 2019 Nov 29.

Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0438DOI Listing
November 2019

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for -Mutant Melanoma.

Cancers (Basel) 2019 Oct 24;11(11). Epub 2019 Oct 24.

Columbia University Irving Medical Center, New York, NY 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11111642DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895913PMC
October 2019

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

J Immunother Cancer 2019 Aug 15;7(1):221. Epub 2019 Aug 15.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0683-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696687PMC
August 2019

The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018.

J Transl Med 2019 05 10;17(1):148. Epub 2019 May 10.

Clinical Trials Unit, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-1892-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509811PMC
May 2019

Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?

J Oncol Pharm Pract 2019 Apr 26;25(3):638-647. Epub 2018 Sep 26.

7 Division of Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155218799850DOI Listing
April 2019

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

J Clin Oncol 2018 Sep 28:JCO2018789602. Epub 2018 Sep 28.

Tara C. Mitchell, University of Pennsylvania; Anthony J. Olszanski, Fox Chase Cancer Center, Philadelphia, PA; Omid Hamid and Ani S. Balmanoukian, The Angeles Clinic and Research Institute, Los Angeles, CA; David C. Smith, University of Michigan, Ann Arbor, MI; Todd M. Bauer, Tennessee Oncology, Nashville, TN; Jeffrey S. Wasser, University of Connecticut School of Medicine, Farmington, CT; Jason J. Luke and Thomas F. Gajewski, University of Chicago Medicine, Chicago, IL; Emmett V. Schmidt, Merck & Co, Kenilworth, NJ; and Yufan Zhao, Xiaohua Gong, Janet Maleski, and Lance Leopold, Incyte Corporation, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.9602DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225502PMC
September 2018

The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma.

Clin Cancer Res 2018 08 2;24(15):3477-3479. Epub 2018 Apr 2.

Division of Hematology/Oncology, Columbia University Medical Center, New York, New York.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-0020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446562PMC
August 2018

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

N Engl J Med 2018 Aug;379(8):722-730

From the University of Texas M.D. Anderson Cancer Center, Houston (H.A.T.); Moffitt Cancer Center and Research Institute, Tampa, FL (P.A.F., N.I.K.); University of California-San Francisco, San Francisco (A. Algazi), the Angeles Clinic and Research Institute, Los Angeles (O.H.), Stanford University Hospital, Palo Alto (R.P.T.), and the Department of Medical Oncology, City of Hope, Duarte (K.M.) - all in California; Dana-Farber Cancer Institute, Boston (F.S.H., D.A.R.); University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill (S.J.M.); University of Colorado Comprehensive Cancer Center, Aurora (K.L.); University of Michigan, Ann Arbor (C.D.L.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (M.A.P.), Roswell Park Cancer Institute, Buffalo (M.S.E., I.P.), and New York University, Lake Success (A.C.P.) - all in New York; Georgetown-Lombardi Comprehensive Cancer Center, Washington DC (M.B.A.); Winship Cancer Institute of Emory University, Atlanta (R.R.K.); University of Pittsburgh Medical Center, Pittsburgh (A.T.); Bristol-Myers Squibb, Princeton, NJ (J.J., A. Avila, S.D.); and Cleveland Clinic-Taussig Cancer Institute, Cleveland (A.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1805453DOI Listing
August 2018

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

J Clin Oncol 2018 06 5;36(17):1658-1667. Epub 2017 Oct 5.

Jason Chesney, J. Graham Brown Cancer Center, University of Louisville, Louisville, KY; Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Philip Friedlander, Mt Sinai School of Medicine, New York, NY; Frances Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Parminder Singh, Mayo Clinic, Phoenix, AZ; Mohammed M. Milhem, University of Iowa Hospitals and Clinics, Iowa City, IA; John Glaspy, University of California Los Angeles School of Medicine; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Lisa Chen, Jenny J. Kim, and Jennifer Gansert, Amgen, Thousand Oaks, CA; Merrick Ross, MD Anderson Cancer Center, Houston, TX; Claus Garbe, University Hospital Tuebingen, Tuebingen; Axel Hauschild, University of Kiel, Kiel, Germany; Theodore F. Logan, Indiana University Simon Cancer Center, Indianapolis, IN; Celeste Lebbé, Assistance Publique-Hôpital De Paris Dermatology and CIC Hôpital Saint Louis University Paris Diderot Sorbonne, Institut National de la Santé et de la Recherche Médicale U976, Paris, France; Robert H.I. Andtbacka, University of Utah, Salt Lake City, UT; and Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.73.7379
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.73.7379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075852PMC
June 2018

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 06 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6270
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6270DOI Listing
June 2018

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

J Immunother 2017 Nov/Dec;40(9):334-340

*Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA †The University of Texas MD Anderson Cancer Center, Houston, TX ‡Memorial Sloan Kettering Cancer Center §Weill Cornell Medical College §§NYU Clinical Cancer Center, New York, NY ∥The Angeles Clinic and Research Institute, Los Angeles ¶Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco ††The John Wayne Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA #Mayo Clinic, Rochester, MN **Mayo Clinic, Jacksonville, FL ‡‡Dana-Farber Cancer Institute, Boston, MA ∥∥Yale Cancer Center, New Haven, CT ¶¶Clinigen, Weybridge, UK ##Merck & Co. Inc., Kenilworth, NJ ***Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00002371-900000000-9951
Publisher Site
http://dx.doi.org/10.1097/CJI.0000000000000186DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5647109PMC
May 2018

The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017.

J Transl Med 2018 04 17;16(1):101. Epub 2018 Apr 17.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-018-1477-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905181PMC
April 2018

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

J Clin Oncol 2018 03 9;36(7):667-673. Epub 2017 Oct 9.

Georgina V. Long, University of Sydney, and Royal North Shore Hospital; Richard Kefford, Macquarie University, Sydney, and Westmead Hospital, Westmead, New South Wales; Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne, Victoria, Australia; Zeynep Eroglu, Moffitt Cancer Center, Tampa, FL; Jeffrey Infante, Tennessee Oncology; Douglas B. Johnson, Vanderbilt-Ingram Cancer Center, Nashville, TN; Sapna Patel, The University of Texas MD Anderson Cancer Center, Houston, TX; Adil Daud, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, University of Colorado, Denver, CO; Lynn Schuchter, University of Pennsylvania, Philadelphia, PA; William Sharfman, Sidney Kimmel Cancer Center, Baltimore, MD; Robert McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University, New Haven, CT; Suman Redhu, Eduard Gasal, and Bijoyesh Mookerjee, Novartis, East Hanover, NJ; Jeffrey Weber, New York University Langone Medical Center, New York, NY; and Keith T. Flaherty, Dana-Farber/Harvard Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.1025
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.1025DOI Listing
March 2018

Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC.

J Thorac Oncol 2017 12 31;12(12):1857-1858. Epub 2017 Jul 31.

The Angeles Clinic and Research Institute, Los Angeles, California; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864173065
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2017.07.024DOI Listing
December 2017

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Melanoma Res 2017 12;27(6):585-590

aDepartment of Internal Medicine, Advocate Medical Group - Oncology North, Park Ridge, Illinois bMelanoma Research Clinic, University of Colorado Cancer Center, Aurora, Colorado cDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia dDepartment of Hematology and Oncology, The University of Arizona Cancer Center, Tucson, Arizona eDepartment of Medicine, Washington University School of Medicine, St Louis, Missouri fDepartment of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee gDepartment of Surgery, Columbia University Medical Center, New York, New York hDepartment of Medical Oncology, Texas Oncology, Dallas, Texas iDepartment of Medicine, Jonsson Comprehensive Cancer Center at University of California jDepartment of Immuno-Oncology, The Angeles Clinic and Research Institute, Los Angeles kDepartment of Oncology, Moores Cancer Center, University of California, San Diego, La Jolla lGenentech Inc., South San Francisco, California mMid Ohio Oncology and Hematology Inc., Columbus, Ohio nDepartment of Melanoma, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC oDepartment of Pathology, University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania pDepartment of Melanoma, Carol G. Simon Cancer Center, Atlantic Health System, Morristown, New Jersey, USA.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00008390-201712000-0000
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000398DOI Listing
December 2017

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.

Cancer Immunol Immunother 2017 Oct 15;66(10):1249-1264. Epub 2017 Jul 15.

Columbia University Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-017-2025-8
Publisher Site
http://dx.doi.org/10.1007/s00262-017-2025-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626801PMC
October 2017

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.

Br J Cancer 2017 Apr 21;116(9):1141-1147. Epub 2017 Mar 21.

Division of Hematology-Oncology, Department of Medicine, University of California, San Francisco, Mount Zion A-743, 1600 Divisadero Street, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.70DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418446PMC
April 2017

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol 2016 12 31;34(34):4102-4109. Epub 2016 Oct 31.

Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.2477
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.2477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562434PMC
December 2016

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Eur J Cancer 2016 11 2;67:46-54. Epub 2016 Sep 2.

Department of Medicine, Division of Hematology-Oncology, Jonsson Comprehensive Cancer Center (JCCC) at the University of California, Los Angeles (UCLA), 10833 Le Conte Ave, Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049163234
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2016.07.018DOI Listing
November 2016

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

N Engl J Med 2016 11 7;375(19):1845-1855. Epub 2016 Oct 7.

From Gustave Roussy Cancer Campus Grand Paris, Villejuif (A.M.M.E., C.R.), Aix-Marseille University, Hôpital de La Timone, Marseille (J.-J.G.), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris (C.L.), University Lille, INSERM Unité-1189, Centre Hospitalier Universitaire (CHU) Lille, Service de Dermatologie, Lille (L.M.), and CHU Lyon, Lyon (L.T.) - all in France; the Oncology Institute of Veneto-Istituto di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Istituti Fisioterapici Ospitalieri, Rome (V.F.), University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), and the European Institute of Oncology, Milan (A.T.) - all in Italy; University of Zurich Hospital, Zurich, Switzerland (R.D.); Memorial Sloan Kettering Cancer Center, New York (J.D.W.); Aarhus University Hospital, Aarhus (H.S.), and Odense University Hospital, Odense (L.B.) - both in Denmark; the Angeles Clinic and Research Institute, Los Angeles (O.H.); Oncology Specialists, Park Ridge, IL (J.M.R.); Cross Cancer Institute, Edmonton, AB, Canada (M.S.); H. Lee Moffitt Cancer Center, Tampa, FL (J.S.W.); Broomfield Hospital, Chelmsford, United Kingdom (S.T.); Universitätsklinikum Schleswig-Holstein, Kiel (A.H.), and University Hospital Heidelberg, Heidelberg (J.C.H.) - both in Germany; Dana-Farber Cancer Institute, Boston (F.S.H.); Bristol-Myers Squibb, Princeton, NJ (C.T., V.P.); and the European Organization for Research and Treatment of Cancer, Brussels (G.S., S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648545PMC
November 2016

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.

J Clin Oncol 2016 09 6;34(26):3119-25. Epub 2016 Jun 6.

Christophe Massard, Institut Gustave Roussy Cancer Centre, Villejuif, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT; Saeed Rafii, Sarah Cannon Research Institute, London, UK; Zev A. Wainberg and Alexandra Drakaki, University of California, Los Angeles; and Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Jason Luke and Peter H. O'Donnell, University of Chicago Comprehensive Cancer Center, Chicago, IL; Tyler J. Curiel, The University of Texas Health Science Center, San Antonio, TX; Gerardo Colon-Otero and Winston Tan, Mayo Clinic, Jacksonville, FL; Rachel E. Sanborn, Providence Cancer Center, Portland, OR; John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, and Ashok Gupta, MedImmune, Gaithersburg, MD; and Neil H. Segal, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.9761DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569690PMC
September 2016

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

J Clin Oncol 2016 08 13;34(22):2619-26. Epub 2016 Jun 13.

Igor Puzanov, Vanderbilt University, Nashville, TN; Mohammed M. Milhem, University of Iowa, Iowa City, IA; David Minor, California Pacific Melanoma Center, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; and Ai Li, Lisa Chen, Michael Chastain, Kevin S. Gorski, Abraham Anderson, and Jeffrey Chou, Amgen, Thousand Oaks, CA; Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; and Robert H.I. Andtbacka, University of Utah, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1529DOI Listing
August 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J Clin Oncol 2016 05 7;34(13):1510-7. Epub 2016 Mar 7.

F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Richard Kefford, Westmead Hospital, Melanoma Institute Australia, and Macquarie University; Peter Hersey, University of Sydney, Sydney, Australia; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; Adil Daud, University of California San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; Caroline Robert, Gustave-Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; Tara C. Gangadhar, Abramson Cancer Center, Philadelphia, PA; Anthony M. Joshua, Princess Margaret Hospital, Toronto, Ontario, Canada; Roxana Dronca, Mayo Clinic, Rochester, MN; Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S. Peter Kang, Scot Ebbinghaus, and Andrea Perrone, Merck, Kenilworth, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547PMC
May 2016

Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.

J Clin Oncol 2016 Mar 11;34(8):833-42. Epub 2016 Jan 11.

David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Jeffrey A. Sosman, Vanderbilt University School of Medicine; Jeffrey R. Infante, Sarah Cannon Research Institute, Nashville, TN; Mario Sznol, Yale Cancer Center, New Haven, CT; Christophe Massard, Gustave Roussy, Villejuif Cedex, France; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Omid Hamid, Angeles Clinic and Research Institute, Santa Monica; Marcella Fassò, Yan V. Wang, Wei Zou, Priti S. Hedge, and Gregg D. Fine, Genentech, South San Francisco, CA; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; and Thomas Powles, Barts Cancer Institute Centre for Experimental Cancer Medicine and the Royal Free National Health Service Trust, Queen Mary University of London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.7421DOI Listing
March 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Future directions for checkpoint inhibition in melanoma.

Authors:
Omid Hamid

Clin Adv Hematol Oncol 2016 Feb;14(2):85-6

The Angeles Clinic and Research Institute, Los Angeles, California.

View Article

Download full-text PDF

Source
February 2016

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

J Clin Oncol 2015 Dec 21;33(34):4023-31. Epub 2015 Sep 21.

Ryan B. Corcoran, Eunice L. Kwak, and David P. Ryan, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Chloe E. Atreya, Adil Daud, and Alan P. Venook, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles, CA; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver; Wells A. Messersmith, University of Colorado Cancer Center and University of Colorado, Aurora, CO; Johanna C. Bendell, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Razelle Kurzrock and Scott Kopetz, University of Texas, MD Anderson Cancer Center, Houston, TX; Mariaelena Pierobon, Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA; Peng Sun, Elizabeth Cunningham, Shonda Little, Keith Orford, Monica Motwani, and Yuchen Bai, GlaxoSmithKline, Philadelphia, PA; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/34/4023.full.pdf
Web Search
http://jco.ascopubs.org/content/suppl/2015/09/21/JCO.2015.63
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.63.2471
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.63.2471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669588PMC
December 2015

Hepatic hemorrhage as a consequence of rapid response to combined targeted therapy in metastatic melanoma.

J Surg Oncol 2015 Dec 26;112(8):844-5. Epub 2015 Oct 26.

Division of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jso.24078
Publisher Site
http://dx.doi.org/10.1002/jso.24078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976480PMC
December 2015

Programmed death 1 immune checkpoint inhibitors.

Clin Adv Hematol Oncol 2015 Dec;13(12):858-68

Columbia University Medical Center, New York, New York.

View Article

Download full-text PDF

Source
December 2015

BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer.

J Clin Oncol 2015 Sep 7;33(25):e101-3. Epub 2014 Apr 7.

The Angeles Clinic and Research Institute, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.49.5622
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.49.5622DOI Listing
September 2015

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

J Clin Oncol 2015 Jun 9;33(17):1889-94. Epub 2015 Feb 9.

Dirk Schadendorf, University Hospital Essen, Essen, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Caroline Robert, Institute Gustave Roussy, Villejuif, France; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; Kim Margolin, University of Washington, Seattle, WA; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Debra Patt, The US Oncology Network, McKesson Specialty Health, Houston, TX; Tai-Tsang Chen, Bristol-Myers Squibb, Wallingford, CT; David M. Berman, Bristol-Myers Squibb, Lawrenceville, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.56.2736
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.2736DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089162PMC
June 2015

A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.

Cancer J 2014 Jan-Feb;20(1):18-24

From the *Karmanos Cancer Center, Wayne State University, Detroit, MI; †The Angeles Clinic and Research Institute, Los Angeles, CA; ‡Washington University, St Louis, MO; §University of Pennsylvania, Philadelphia, PA; ∥Oncology Specialists S.C., Park Ridge, IL; ¶University of Colorado Cancer Center, Aurora, CO; #Baylor Sammons Cancer Center, Texas Oncology, PA, Dallas, TX; **NYU Medical Center, New York, NY; ††South Carolina Oncology Associates, Columbia, SC; ‡‡Providence Portland Medical Center, Portland, OR; §§Winship Cancer Institute, Emory University, Atlanta, GA; ∥∥Memorial Sloan Kettering Cancer Center, New York, NY; ¶¶Seattle Cancer Care Alliance, Seattle, WA; ##UCLA School of Medicine, Los Angeles, CA; ***Beth Israel Deaconess Medical Center and †††Massachusetts General Hospital, Boston, MA; ‡‡‡University of Arizona Cancer Center, Tucson, AZ; §§§Dana Farber Cancer Institute, Boston, MA; ∥∥∥Genentech, San Francisco, CA; ¶¶¶The SFJ Pharma Group, Pleasanton, CA; and ###Sarah Cannon Research Institute, Nashville, TN.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/journalppo/2014/01000/A_Single_
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PPO.0000000000000024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705837PMC
May 2015

Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.

Am J Clin Oncol 2015 Feb;38(1):61-7

*Northern California Melanoma Center, St. Mary's Medical Center, San Francisco †The Angeles Clinic and Research Institute, Santa Monica ‡Scott Cruickshank and Associates, Santa Barbara, CA.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/COC.0b013e318287bbaeDOI Listing
February 2015

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

J Clin Oncol 2014 Nov 29;32(32):3659-66. Epub 2014 Sep 29.

Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.54.8115
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.8115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879709PMC
November 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.

Authors:
Omid Hamid

Clin Adv Hematol Oncol 2014 Nov;12(11):782-4

The Angeles Clinic and Research Institute, Los Angeles, CA.

View Article

Download full-text PDF

Source
November 2014

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Clin Cancer Res 2014 Sep 23;20(17):4449-58. Epub 2014 Jun 23.

Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0887DOI Listing
September 2014

Selecting patients for KIT inhibition in melanoma.

Methods Mol Biol 2014 ;1102:137-62

Melanoma/Sarcoma Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-62703-727-3_9
Publisher Site
http://dx.doi.org/10.1007/978-1-62703-727-3_9DOI Listing
June 2014

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.

Front Oncol 2014 16;4:110. Epub 2014 May 16.

Dirks/Dougherty Laboratory for Cancer Research, Department of Translational Immunology, John Wayne Cancer Institute at Saint John's Health Center , Santa Monica, CA , USA.

View Article

Download full-text PDF

Source
http://journal.frontiersin.org/article/10.3389/fonc.2014.001
Publisher Site
http://dx.doi.org/10.3389/fonc.2014.00110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032905PMC
June 2014

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Clin Cancer Res 2014 May 14;20(9):2457-65. Epub 2014 Mar 14.

Authors' Affiliations: Departments of Medicine, Surgery, Pathology and Laboratory Medicine, Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology; Jonsson Comprehensive Cancer Center; Department of Ophthalmology, Jules Stein Eye Institute; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research; Howard Hughes Medical Institute, University of California, Los Angeles (UCLA); The Angeles Clinic Research Institute, Los Angeles; Department of Medicine, University of California San Diego (UCSD) Moores Cancer Center, La Jolla; Divisions of Chemistry and Biology, California Institute of Technology, Pasadena, California; Department of Medical and Molecular Genetics, Indiana University, and the Indiana University Viral Production Facility (IU VPF), Indianapolis, Indiana; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada; Mayo Clinic Scottsdale, Scottsdale, Arizona; Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut; and Center for Immunology, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-3017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070853PMC
May 2014

Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.

Clin Cancer Res 2014 Mar 13;20(5):1335-44. Epub 2014 Jan 13.

Authors' Affiliations: Cleveland Clinic, Cleveland, Ohio; Takeda Pharmaceuticals International Company; Millennium: The Takeda Oncology Company, Cambridge, Massachusetts; University of Chicago, Chicago; NorthShore University Health System, Evanston; Northwestern University Feinberg School of Medicine, Chicago, Illinois; Florida Cancer Specialists, Fort Myers, Florida; The Angeles Clinic & Research Institute, Los Angeles; University of Southern California Westside Cancer Center, Beverly Hills, California; and Sarah Cannon Cancer Research Institute, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2014/02/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-2436DOI Listing
March 2014

Nonsurgical treatment options for basal cell carcinoma - focus on advanced disease.

J Drugs Dermatol 2013 Dec;12(12):1369-78

View Article

Download full-text PDF

Source
December 2013

Identifying patients at risk for recurrent or advanced BCC.

J Drugs Dermatol 2013 Nov;12(11):1246-52; quiz 1253-4

View Article

Download full-text PDF

Source
November 2013

Understanding BCC pathogenesis: treatment advancements and challenges.

J Drugs Dermatol 2013 Oct;12(10):1110-20

View Article

Download full-text PDF

Source
October 2013

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

J Clin Oncol 2013 Sep 5;31(26):3205-11. Epub 2013 Aug 5.

Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.49.8691
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.49.8691DOI Listing
September 2013

Is IL-2 still indicated for melanoma and RCC? What a question to ask!

Authors:
Omid Hamid

Oncology (Williston Park) 2013 Jul;27(7):695, 701

Melanoma Clinic, The Angeles Clinic and Research Institute, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
July 2013